By Karen Roman ReAlta Life Sciences said it is presenting new data at the American Society of Hematology (ASH) Annual Meeting in San Diego, California for its drug candidate in acute Graft-versus-Host Disease (aGVHD), pegtarazimod. The study showed significant improvement...

By Daniella Nanox (Nasdaq: NNOX), received FDA clearance to produce tomographic images for broader diagnostic applications, the company said. Nanox.ARC, now deployed in healthcare facilities across seven U.S. states, utilize proprietary tomosynthesis technology with a cold cathode, the system delivers...

By Karen Roman OmniScience and INmune Bio, Inc. (Nasdaq: INMB) said they’re using genAI in an Alzheimer’s disease trial. The AI will support the live clinical trial and is expected to increase efficiency and the probability of success, both companies...

  By Karen Roman Agendia, Inc. said its gene expression profiling test MammaPrint can predict extended endocrine therapy benefit for patients with early-stage breast cancer. The test helps optimizing additional therapy and can potentially improve survival, the company said. “These...

By Daniella Parra ReAlta Life Sciences said it appointment Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of its Board of Directors, as it continues to rebalance the inflammatory response to address rare and acute inflammatory diseases across a wide spectrum...

By Daniella Parra MOBILion Systems, Inc. said it formed a Proteomics Advisory Board of seven prominent experts to guide its efforts in proteomics, focusing on advancing complex sample analysis technology. The approach aims to revolutionize mass spectrometry by enabling precise...

By Daniella Parra Medera Inc. and CADENCE have launched Asia’s first cardiac gene therapy trial for heart failure in Singapore, they said. The trial uses SRD-001, an adeno-associated virus-based therapy targeting heart failure with reduced ejection fraction, they said. “The...

By Karen Roman Healthcare apparel brand FIGS, Inc. (NYSE: FIGS) said it expects flat net revenue growth and an adjusted EBITDA margin around 8% for fiscal year 2024. Net revenue was $140.2 million in the third quarter, down 1.5%, while...

By Karen Roman Radella Pharmaceuticals, LLC. announced the successful trial results of MD-18, its leading program to treat obesity and diabetes. The company will start the next phase applying multiple doses of MD-18 before the end of the year, it...

By Karen Roman DecisionRx said it appointed Michael Tilton as Chief Growth Officer to lead the expansion of the company’s Medication Therapy Optimization platform. Tilton’s previous roles include senior vice president at Humana, as well as other senior leadership positions...